URTH - CryoLife Inc.: Regulatory Tailwinds For FY2021 23% Upside Potential

• CryoLife continues to perform on recent fundamental and technical momentum, where shareholders have enjoyed +25% upside YTD.
• The company is well positioned to benefit from market crosscurrents in global supply chain logistics and growth in key end-markets in FY2021.
• Product sales have increased organically YoY, however, as much did not carry through to the bottom line in Q1.
• Here, CryoLife is benchmarked against an already outperforming portfolio of US listed healthcare equities on 3 metrics to justify investment.
• On a valuation of 13.7x FY2021 sales estimates of ~$295 million this yields a price target of $35.35, ~23% upside potential on today.

For further details see: